MODERATOR
:
SPEAKER
(S):
Jeffrey Jhang, MD, Associate Professor of Clinical Pathology and Cell Biology, College of Physicians and Surgeons of Columbia University
ABO Non-Identical Hematopoietic Progenitor Cell Transplants:Processing and Transfusion Management
Dr. Anand Padmanabhan, MD, PhD, MA, Medical Director, Bloodcenter of Wisconsin - Wauwatosa Donor Center
Description
ABO incompatibility is not considered a barrier to successful HSCT. It occurs in 40-50% of all allogeneic HSCTs and requires the careful attention of the recipient's physician as well as the transfusion and cell processing facilities staff. This audioconference will describe current approaches in dealing with ABO-incompatible HSCT in order to lessen potential complications and optimize favorable outcomes. The speakers will discuss patient related issues including testing, transfusion policies, infusion practices, and post transplant monitoring. In addition, cellular product testing, processing methods and criteria for acceptability will be reviewed.
-
Describe appropriate processing methodologies, expected end points and release criteria for cellular products used in ABO- incompatible HSCT.
-
Discuss potential consequences and transplant outcomes in the ABO-incompatible HSCT setting.
-
Review approaches to safe product infusion, post transplantation monitoring and transfusion policies for ABO-incompatible HSCT recipients.
-
Review relevant testing performed on ABO- incompatible HSCT recipients including methodologies, limitations and utilizations.
CE Category | CE Value |
---|
California Clinical Laboratory Personnel |
1.5 |
California Nurse |
1.8 |
Florida Laboratory Personnel |
1.8 |
General Attendee |
1.5 |
Physician |
1.5 |
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.